Tonix is recruiting individuals for research studies in:
Military-Related PTSD, Fibromyalgia and Episodic Tension-Type Headache.

Click here for more information.

Changing the Landscape

Millions of Americans suffer from central nervous system (CNS) disorders. Tonix Pharmaceuticals is developing medicines to help.

Learn more

Latest News

Tonix Pharmaceuticals Presents Additional Data on Tonmya(TM) Demonstrating Improvements in Sleep, Pain, and Other Outcomes in Fibromyalgia at 2015 ACR/ARHP Annual Meeting

• November 10, 2015 • 8:30 AM EST

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix"), which…

Read more

Management Team

Our experienced team has a strong track record of success in drug approvals and value creation. Learn more about the management team at Tonix Pharmaceuticals.

View Management

Clinical Pipeline

Tonix's lead product candidate, TNX-102 SL, is being developed for the treatment of Fibromyalgia and PTSD. Tonix is developing TNX-201 for the treatment of Episodic Tension-Type Headache.

View Pipeline

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage company developing next-generation medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden.

Learn more about tonix